Drug intelligence / Profile preview

ICP-490

Development stage: Phase 2
Lead developer: InnoCare Pharma
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

ICP-490 is an orally available, next-generation small molecule immunomodulatory imide drug (IMiD) developed by InnoCare Pharma for the treatment of multiple myeloma and non-Hodgkin's lymphoma. It functions as a molecular glue degrader, specifically binding to the CRL4CRBN-E3 ligase complex to induce ubiquitination and degradation of transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), which are critical for tumor cell survival in hematologic malignancies. This mechanism allows ICP-490 to overcome resistance seen with earlier-generation cereblon modulators such as lenalidomide. Preclinical studies have demonstrated potent anti-tumor activity against multiple myeloma and non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma (DLBCL), with minimal cytotoxicity toward normal cells. The drug is currently in phase 2 clinical trials for relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma[1][2][4][5][6].

Other names: ICP 490ICP490ICP-490

Targets

CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)

Beyond the preview

Go deeper on ICP-490.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICP-490.

Explore the full profile